Our member BerGenBio is currently testing the company’s cancer medicine as a potential treatment for Covid-19.
Another one of our members has emerged this year as an active contributor in the fight against the corona pandemic. BerGenBio, a Norwegian clinical-stage biopharmaceutical company, is running a clinical trial to assess the safety of the company’s cancer drug to treat Covid-19 patients.
BerGenBio develops novel selective AXL kinase inhibitors, an advanced type of cancer treatment. In cancer, AXL suppresses the body’s immune response to tumours. In many different cancer indications, AXL can be the reason that treatments fail.
BerGenBio’s primary drug candidate is called Bemcentinib and is currently being investigated in several ongoing cancer clinical trials, against both lung cancer and leukaemia.
This year, BerGenBio announced the company will also test the drug as a treatment for hospitalised Covid-19 patients. The phase II study, which will recruit a total of 120 patients hospitalised with Covid-19 at different sites in India and South Africa, recruited its first patient in India this week.
“We are pleased to expand the BGBC020 study to patients in India, where incidences of COVID-19 remain high, following the commencement of dosing in South Africa in October,” Richard Godfrey, Chief Executive Officer of BerGenBio, commented. “There are still no approved therapies for patients hospitalised as a result of COVID-19 infection and we are keen to continue exploring the profile of bemcentinib as a potential treatment.”
- Read the press release from BerGenBio here: BerGenBio confirms first patient enrolled in phase II trial assessing bemcentinib as a potential treatment for COVID-19 patients in India
Promising solutions from health industry
BerGenBio is one of our many members that have joined the effort against corona this year with their science, technology and knowledge.
Another example is the Norwegian biotechnology company Vaccibody, who have used the company’s cancer vaccine technology to expand their activities to do research into infectious diseases.
Similarly, our member NEC OncoImmunity has adapted the company’s artificial technology platform for improving cancer immunotherapies to design vaccine blueprints against the coronavirus.
Moreover, our member the Norwegian start-up company Ledidi has contributed with a data-sharing software that will be used to increase research collaboration in Oslo University Hospital’s clinical trials on Covid-19.
Several of the larger pharmaceutical companies in our membership base are also in the race to deliver effective vaccines against the coronavirus in 2021.
The corona pandemic has left many sectors of society across the world struggling, but the health industry has proved that it holds promising solutions to a global challenge. Medical innovations and the enthusiasm of researchers continue to shine a positive light at the end of this tunnel.